Amide-linked Ethanolamine Conjugate of Gemfibrozil as a Profound HDL Enhancer: Design, Synthesis, Pharmacological Screening and Docking Study

Author(s): Himanshu Rai , Suneela S. Dhaneshwar .

Journal Name: Current Drug Discovery Technologies

Volume 12 , Issue 3 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Elevated concentration of any or all types of lipids in the plasma including hypertriglyceridemia and hypercholesterolemia leads to atherosclerotic cardiovascular disease. Effective medication needs multiple drug therapy as recommended cholesterol and triglyceride levels are difficult to achieve by monotherapy and frequently require the use of more than one lipid-lowering medication. Gemfibrozil lowers plasma triglyceride-rich lipoproteins mainly VLDL and increases HDL. It is associated with short plasma half-life (1.5h) and GIT distress on long term use. In a study it was found that ethanolamine decreases serum cholesterol, especially VLDL cholesterol and LDL cholesterol in rats fed an HF/HC diet. In the present work, we thought of exploring the effect of co-drug of gemfibrozil with ethanolamine (GE-I) as a potential combination therapy for the management of mixed hyperlipidemia. Synthesis of GE-I was effected by CDI coupling. Structure was confirmed spectrally. Interestingly kinetic studies revealed that GE-I resisted chemical and enzymatic hydrolysis. In tritoninduced hyperlipidemia, significant lowering of serum lipid levels was observed. The hallmark of GEI was its profound effect on HDL level which was raised above the normal level by 15%. Docking study also supported modulatory effect of GE-I (docking score -7.012) on PPAR-α which was comparable to docking score of gemfibrozil (-9.432). These preliminary observations prompt us to consider GE-I as a novel, serendipitous, hybrid anti-hyperlipidemic new chemical entity which needs be studied extensively to prove it as an HDL enhancing anti-hyperlipidemic agent.

Keywords: Ethanolamine, gemfibrozil, HDL enhancer, hybrid drug, mixed hyperlipidemia, PPARα activator.

[2]
Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 1998; 1801-7.
[3]
http://www.americanheart.org/statistics (American Heart Association: 2001 Heart and Stroke Statistical Update Dallas Texas: American Heart Association 2000).(Accessed on 11/03/12)
[4]
www.indstate.edu/theme/mwking/lipid (Accessed on 03/03/12)
[5]
Michael P. Process for preparing a crystalline form of atorvastatin hemi-calcium WO 2007/103223 A1, 2007.
[6]
Roth BD. [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy- 5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof US 5,273,995, 1993.
[7]
Srinivasulu G, Srinivas K, Satyanarayana K, Satyanarayanajaya K. WO 2006/039443 A2 2006.
[8]
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
[9]
Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
[10]
Steiner S, Niessner A, Ziegler S, et al. Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis 2005; 181: 305-10.
[11]
Qandil AM, Rezigue MM, Tashtoush MM. Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. Eur J Pharm Sci 2011; 43: 99-108.
[12]
Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-42.
[13]
Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: From orphan receptors to drug discovery. J Med Chem 2000; 43: 527-50.
[14]
Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001; 3: 83-92.
[15]
Aberg F, Appelkvist EL, Broijersen A, et al. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. Eur J Clin Invest 1998; 28: 235-42.
[16]
Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34: 155-62.
[17]
Lovreka M, Zorc B, Boneschans B, Butula I. Macromolecular prodrugs. VIII. Synthesis of polymer – gemfibrozil conjugates. Int J Pharm 2000; 200: 59-66.
[18]
Lupp A, Karge E, Hopf H, Machts H, Oelschläger H, Fleck C. Fibrates and their newly synthesized glycinate or glycinate-methylester derivatives: Comparison of the interactions with liver cytochrome P450 dependent monooxygenase- and oxidase-functions in vitro. Exp Toxicol Pathol 2003; 54: 433-40.
[19]
Jensen GR. Handbook of milk composition, San Diego 1975. CA: Academic Press Inc 1995.
[20]
Sunder R, Akesson B. Regulation of phospholipid biosynthesis in isolated rat hepatocytes. J Biol Chem 2006; 250: 3350-67.
[21]
Delong CJ, Shen YJ, Thomas MJ, Cui Z. Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway. J Biol Chem 1999; 274: 29683-8.
[22]
Reo NV, Adinehzadeh M, Foy BD. Kinetic analysis of liver phosphatidylcholine and phosphatidylethanolamine biosynthesis using d13TC NMR spectroscopy. Biochim Biophys Acta 2002; 1580: 171-88.
[23]
Watkins MS, Zhu X, Zeisel HS. Phosphatidylethanolamine-N methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. J Nutr 2003; 133: 3386-91.
[24]
Shimada Y, Morita T, Sugiyama K. Dietary eritadenine and ethanolamine depress fatty acid desaturase activities by increasing liver microsomal phosphatidylethanolamine in rats. J Nutr 2003; 133: 758-65.
[25]
Imaizumi K, Sakano M, Wawatari K, Murata M, Sugano M. Effect of phosphatidylethanolamine and its constituent base on the metabolism of linoleic acid in rat liver. Biochim Biophys Acta 1989; 1005: 253-9.
[26]
Kume H, Tsukahara K, Okazaki K, Sasaki H. Milk-derived phospholipids prevent the development of hypercholesterolemia and hepatic steatosis in rats fed high cholesterol/triglyceride diets. J Metab Clin Nutr 2004; 3: 187-95.
[27]
Kume H, Tsukahara K, Okazaki K, Sasaki H. Ethanolamine improves hypercholesterolemia in rats fed high-fat/high-cholesterol diets. Nutr Res 2006; 26: 573-8.
[28]
Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: Design and clinical applications. Nat Rev Drug Discov 2008; 7: 255-70.
[29]
Cynkowska G, Cynkowski T, Al-Ghananeem AM, Guo H, Ashton P, Crooks PA. Novel antiglaucoma prodrugs and codrugs of ethacrynic acid. Bioorg Med Chem Lett 2005; 15: 3524-7.
[30]
Dhaneshwar SS, Gairola N, Kandpal M, et al. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon specific drug delivery in inflammatory bowel disease. Eur J Med Chem 2009; 44: 3922-9.
[31]
Hamad MO, Kiptoo PK, Stinchcomb AL, Crooks PA. Synthesis and hydrolytic behavior of two novel tripartite codrugs of naltrexone and 6β-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agent. Bioorg Med Chem 2006; 14: 7051-61.
[32]
Abdel-Azeem AZ, Abdel-Hafez AA, El-Karamany GS, Farag HH. Chlorzoxazone esters of some non-steroidal anti-inflammatory (NSAI) carboxylic acids as mutual prodrugs: Design, synthesis, pharmacological investigations and docking studies. Bioorg Med Chem 2009; 17: 3665-70.
[33]
Sudha SS, Karthic R, Naveen RJ. Anti hyperlipidemic activity of Spirulina platensis in Triton X-100 induced hyperlipidemic rats. Hygeia J D Med 2011; 3: 32-7.
[34]
Glide; Maestro, version 90, Schrödinger, LLC, New York, NY,. 2009.
[35]
LigPrep, version 23, Schrödinger, LLC, New York, NY,. 2009.
[36]
Bernardes A, Souza PCT, Muniz JRC, et al. Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: A new mode of ligand recognition and receptor stabilization. J Mol Biol 2013; 423: 2878-93.
[37]
Teli MK, Rajanikant GK. Identification of novel potential HIF-prolyl hydroxylase inhibitors by in silico screening. Mol Divers 2012; 16: 193-202.
[38]
QikProp, version 32, Schrödinger, LLC, New York, NY. 2009.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 3
Year: 2015
Page: [155 - 169]
Pages: 15
DOI: 10.2174/1570163812666150819095640
Price: $58

Article Metrics

PDF: 35
HTML: 3
EPUB: 1
PRC: 3